Fourth quarter 2022 GAAP revenues of $27.0 million ; Core product and service revenues of $26.8 million , representing 8.3% sequential growth; Full year GAAP revenues of $97.9 million and core product and service revenues of $94.5 million Improved operating discipline and restructuring initiatives
SOUTH SAN FRANCISCO, Calif. , Jan. 31, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report fourth quarter and full year 2022 financial results on Tuesday,
Continued commercial and strategic execution delivers sequential core revenue growth of 4% – 9% to $26 million – $27 million in Q4 2022 for full year total of approximately $94 million – $95 million Business restructuring and SBS program on track to deliver over 20% reduction in operating
Former Danaher Executive Further Strengthens Senior Management Team SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the appointment of
SOUTH SAN FRANCISCO, Calif. , Nov. 28, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that its board of directors has authorized the repurchase of up to $20 million of shares of
SOUTH SAN FRANCISCO, Calif. , Nov. 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of November 20, 2022 , under the
Third quarter core product and services revenue increase of 30% sequentially to $24.8 million First phase of restructuring program improves operating margin by 600 to 800 basis points, or $8.0 million net on an annualized basis Reiterate stated goal of 700 to 1000 basis point non-GAAP product and
Seamlessly linking the Standard BioTools portfolio of Imaging Mass Cytometry (IMC) systems with Visiopharm AI-driven software for phenotyping cells in high-plex imaging SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022,
SOUTH SAN FRANCISCO, Calif. , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that Ascendas Genomics has received approval from the National Medical Products
